Could a daily cannabinoid pill shield Athletes' brains from concussion?

NCT ID NCT07715864

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a daily broad-spectrum cannabinoid capsule can protect the brain and speed recovery from concussion in healthy male athletes who play contact sports. Participants take either the active capsule or a placebo twice daily, and researchers measure brain blood flow, inflammation markers, and concussion rates. The goal is to see if this natural compound can reduce injury and support brain health during high-impact competition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a broad-spectrum cannabinoid formulation in a gel capsule
What this could lead to
If it works, this could point toward a daily supplement that reduces concussion risk and speeds brain recovery in contact-sport athletes.
What could go wrong
This is a small early-phase trial in healthy male athletes only, so results may not apply to others. The cannabinoid formulation may cause side effects or fail to show a protective effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 35 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male adults between 19-35 years of age that compete in contact sport athletics. * Participants with no known cerebrovascular or cardiovascular complications. * Participants will not be habitual recreational users of cannabis (i.e., \<1 day/week) or tobacco users. * Participants that agree not use any other cannabis or tobacco products while enrolled in the study. * Participants willing to provide a list of any prescription medications they are taking. * Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests. * Participants who are capable of giving signed informed consent. Exclusion Criteria: * Female. * Must not travel to the USA during study period; USA laws do not permit cross border with cannabis products. * Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2-month period without use of cannabis-based therapy prior to enrollment in the study). * Participants with any level of cannabis in their blood samples when sampled at the commencement of the study will be excluded. * Participants that are being medically supervised for anxiety, depression, Post Traumatic Stress Disorder (PTSD), mood disorder, psychotic disorders or any cerebrovascular and cardiovascular complications. * Participants who are taking prescription medications such as psychotropic medications with serotonergic activity, including Selective Serotonin Reuptake Inhibitors (i.e. Fluoxetine), Tricyclic Antidepressants (i.e. Elavil, Nortriptyline) and Atypical Neuroleptics (i.e. Risperidone, Seroquel). * Initiation or dosage change of oral or injected steroids within 3 months. * Allergy or known intolerance to any of the compounds within the study preparation. * Unable to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, and functional motor skills laboratory tests. * Inability of study participants to attend assessments on a regular basis at the pre-determined times, or failure to take the drug daily. * Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator). * If they already have a concussion at the time of starting the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Brain Concussion cannabis dependence Color Vision Defects Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Regina

    RECRUITING

    Regina, Saskatchewan, S4S-0A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.